Welcome to our dedicated page for Charles Riv Labs Intl news (Ticker: CRL), a resource for investors and traders seeking the latest updates and insights on Charles Riv Labs Intl stock.
News about Charles River Laboratories International, Inc. (NYSE: CRL) focuses on its role in research and development in biotechnology and its activities as a contract research and manufacturing partner to pharmaceutical, biotechnology, government, and academic clients. Company updates often highlight how Charles River’s research models, discovery and safety assessment services, and manufacturing solutions support the discovery, early-stage development, and safe manufacture of new therapies.
Investors and industry followers can expect frequent news on strategic transactions and partnerships. Recent announcements include planned acquisitions such as K.F. (Cambodia) Ltd., a provider of non-human primates for regulatory-required biomedical, pharmaceutical, and toxicological research, and PathoQuest SAS, a provider of next-generation sequencing solutions for manufacturing quality-control testing. The company also reports collaborations, for example with The Francis Crick Institute on antibody-drug conjugate discovery and with X-Chem, Inc. to expand hit identification capabilities using DNA-encoded library technology.
Charles River’s news flow also covers scientific and operational initiatives. The company has announced the creation of a Scientific Advisory Board led by Dr. Namandjé N. Bumpus to advance New Approach Methodologies (NAMs) and reduce reliance on animal testing, as well as the expansion of its Cell & Gene Therapy Incubator Program to support early-stage advanced therapy developers and enabling technology companies. Updates on its strategic review, portfolio refinement, restructuring initiatives, and capital deployment plans provide additional context on long-term positioning and financial priorities.
Governance and leadership developments are another recurring theme, such as the planned CEO succession and the appointment of a Chief Scientific and Innovation Officer. Earnings releases and conference presentations offer insight into demand trends across the Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions segments. For readers tracking CRL, this news page brings together these earnings updates, transaction announcements, scientific collaborations, and strategic milestones in one place.
Charles River Laboratories (NYSE: CRL) will release its third-quarter 2025 financial results on Wednesday, November 5, 2025 before the market opens. A conference call to discuss the results is scheduled the same day at 9:00 a.m. ET. Investors can listen to a live webcast and access a replay via the company's Investor Relations website at ir.criver.com.
Charles River (NYSE: CRL) and Toxys announced a collaboration on October 8, 2025 to offer Charles River clients access to ReproTracker, a human stem cell–based in vitro assay for rapid identification of developmental toxicity hazards. The assay complements traditional DART methods, can quantitatively predict teratogenic potential, and may serve as an early-phase screening platform or animal-free alternative for pharmaceuticals, agrochemicals and industrial chemicals.
The collaboration is positioned under Charles River’s Alternative Methods Advancement Project™ (AMAP™) and reinforces use of New Approach Methodologies (NAMs) and the 3Rs while leveraging Charles River’s DART services and historical control database.
Charles River Laboratories (NYSE: CRL) announced that CFO Flavia H. Pease will resign effective September 29, 2025, to pursue another opportunity. Michael G. Knell, current Corporate Senior Vice President and Chief Accounting Officer, has been appointed as interim CFO while the company conducts a comprehensive search for a permanent replacement.
The company has reaffirmed its 2025 financial guidance for revenue and non-GAAP earnings per share, which was previously provided on August 6, 2025, supported by current third-quarter performance outlook. CEO James C. Foster expressed confidence in Knell's ability to lead the finance organization during the transition period, citing his valuable experience since joining the company in 2017.
Charles River Laboratories (NYSE:CRL) has announced two strategic collaborations to advance oncology research and development through its contract development and manufacturing organization (CDMO). The company has formed an alliance with the Parker Institute for Cancer Immunotherapy (PICI), providing PICI network members access to Charles River's preclinical drug discovery and development services.
Additionally, Charles River will support Children's Hospital Los Angeles (CHLA) in manufacturing materials for a Phase I Clinical Trial, leveraging CHLA's $6 million award from the California Institute for Regenerative Medicine. The company's expanded cell and gene therapy portfolio offers comprehensive "concept-to-cure" advanced therapies solutions, focusing on plasmid DNA, viral vector, and cell therapy services.
Charles River Laboratories (NYSE:CRL) has announced its participation in two major healthcare investor conferences in September 2025. The company will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9th at 10:00 a.m. EDT and the Baird 2025 Global Healthcare Conference on September 10th at 9:40 a.m. EDT.
Management will provide an overview of the company's strategic focus, business developments, and recent trends. Both presentations will be accessible via live webcast through the company's investor relations website, with replays available for at least two weeks after the events.
Charles River Laboratories (NYSE:CRL) has enhanced its Cell Therapy Flex Platform through a collaboration with Akadeum Life Sciences. The partnership integrates Akadeum's GMP-grade Human T Cell Leukopak Isolation Kit, featuring innovative Microbubble technology for cell separation.
The technology uses gravity-based isolation of T cells, offering a scalable and GMP-compliant solution that can be implemented without additional capital investment. The process can be performed directly in the apheresis bag, simplifying the workflow. This enhancement follows Charles River's recent integration of Akron Bio's Closed System Solutions line of liquid cytokines, further streamlining their cell therapy operations.
The Cell Therapy Flex Platform serves as an off-the-shelf solution for Cell Therapy Process Development, specifically validated for autologous CAR-T and TCR-T cell therapies, aiming to reduce risks, costs, and development timelines.Charles River Laboratories (NYSE: CRL) has joined the EASYGEN Consortium, an EU-backed initiative aimed at revolutionizing CAR-T cell therapy manufacturing. The consortium's primary goal is to develop an automated, hospital-based platform capable of producing personalized cell therapies within 24 hours.
Charles River will contribute by developing an ex vivo 3D screening platform that leverages their patient-derived xenograft (PDX) bank and high-content imaging to quickly identify safe and effective CAR-T cell candidates. This initiative addresses a critical need, as currently less than 20% of eligible patients receive CAR-T therapy due to complex manufacturing processes and supply chain limitations.
The EASYGEN Consortium, comprising 18 partners across 8 countries, aims to transform CAR-T production from weeks to days, making these life-saving treatments more accessible and affordable while reducing hospital staff workload.
Charles River Laboratories (NYSE: CRL) reported Q2 2025 results with revenue of $1.03 billion, a slight increase of 0.6% from Q2 2024. The company's GAAP EPS decreased to $1.06 from $1.74, while non-GAAP EPS increased 11.4% to $3.12.
Key segment performance showed mixed results: Research Models and Services (RMS) revenue grew 3.3% to $213.3M, Discovery and Safety Assessment (DSA) revenue declined 1.5% to $618.0M, and Manufacturing Solutions revenue increased 4.4% to $200.8M.
The company updated its 2025 guidance, now expecting organic revenue decline of (3.0)% to (1.0)% and non-GAAP EPS of $9.90-$10.30. Notably, the U.S. Department of Justice closed its investigation into the company's non-human primate supply chain.
[ "Non-GAAP EPS increased 11.4% to $3.12 per share", "Non-GAAP operating margin improved to 22.1% from 21.3%", "Manufacturing Solutions segment revenue grew 4.4% to $200.8M", "U.S. DOJ closed investigation into non-human primate supply chain", "Company raised full-year guidance for revenue and non-GAAP EPS" ]Charles River Laboratories (NYSE:CRL) announced plans to explore a strategic partnership with BioTech Social Inc. (BSI) to integrate crowdfunding capabilities into their Incubator (CIP) and Accelerator (CAP) Programs. The collaboration would enable early-stage cell and gene therapy developers to raise up to $5 million annually through BSI's BioTech Funding Portal.
The partnership aims to help biotech companies bridge the funding 'valley of death' by connecting them with non-accredited investors. This initiative builds upon Charles River's 2024-established CIP and CAP programs, which provide regulatory expertise, laboratory space, and equipment access. The companies plan to evaluate applications for the next cohort in conjunction with the upcoming European Cell and Gene Therapy Summit in September 2025.
Charles River Laboratories (NYSE: CRL) has entered into a strategic CDMO agreement with Elly's Team, a parent-led foundation focused on developing treatments for NEDAMSS, an ultra-rare genetic disorder. The collaboration leverages Charles River's Cell and Gene Therapy Accelerator Program to manufacture critical materials for Phase I clinical trials.
The partnership has already achieved significant success, with Elly becoming the first patient to receive IRF2BPL gene replacement therapy on April 3, 2025. The treatment received FDA approval in March 2025, just 13 months after diagnosis. Elly's Team utilized Charles River's eXpDNA™ platform and AAV Rep/Cap plasmids, reducing manufacturing efforts by up to 66 percent.
NEDAMSS, caused by IRF2BPL gene mutations, affects fewer than 150 cases worldwide and impacts motor skills, speech, eating, eyesight, and can cause seizures.